Last reviewed · How we verify
Epoetin Hospira Arm
Epoetin alfa is a recombinant erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells.
Epoetin alfa is a recombinant erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells. Used for Anemia associated with chronic kidney disease, Anemia in patients with cancer receiving chemotherapy, Anemia in patients undergoing elective surgery.
At a glance
| Generic name | Epoetin Hospira Arm |
|---|---|
| Also known as | ESA, Erythropoetin Stimulating Agent, Erythropoetin Stimulation Agents |
| Sponsor | Pfizer |
| Drug class | Erythropoiesis-stimulating agent (ESA) |
| Target | Erythropoietin receptor (EPOR) |
| Modality | Biologic |
| Therapeutic area | Hematology |
| Phase | Phase 3 |
Mechanism of action
Epoetin alfa is a biosynthetic form of human erythropoietin (EPO), a hormone that regulates red blood cell production. It binds to EPO receptors on erythroid progenitor cells in the bone marrow, promoting their proliferation and differentiation into mature red blood cells. This increases hemoglobin levels and oxygen-carrying capacity in patients with anemia.
Approved indications
- Anemia associated with chronic kidney disease
- Anemia in patients with cancer receiving chemotherapy
- Anemia in patients undergoing elective surgery
Common side effects
- Hypertension
- Headache
- Thrombotic events (DVT, PE, stroke)
- Pure red cell aplasia
- Injection site reactions
Key clinical trials
- A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis (PHASE3)
- A Study Comparing the Effects of Epoetin Hospira and Epogen/Epoetin Alfa (Amgen) When Administered IV in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment (PHASE1)
- Erythropoietin (EPO) to Protect Renal Function After Cardiac Surgery (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Epoetin Hospira Arm CI brief — competitive landscape report
- Epoetin Hospira Arm updates RSS · CI watch RSS
- Pfizer portfolio CI